Gladius Capital Management LP Regeneron Pharmaceuticals, Inc. Transaction History

Gladius Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 18, 2023	BUY	$700.03 - $830.35 $5.71 Million - $6.77 Million	8,150 New	8,150 $5.86 Million
Q2 2023 Aug 08, 2023	BUY	$700.03 - $830.35 $2.26 Million - $2.68 Million	3,223 Added 65.42%	8,150 $5.86 Million
Q1 2023 Dec 18, 2023	BUY	$680.49 - $826.97 $3.35 Million - $4.07 Million	4,927 New	4,927 $4.05 Million
Q1 2023 May 09, 2023	BUY	$680.49 - $826.97 $3.35 Million - $4.07 Million	4,927 New	4,927 $4.05 Million
Q2 2022 Aug 10, 2022	BUY	$548.35 - $738.84 $8,225 - $11,082	15 New	15 $9,000
Q1 2022 Apr 29, 2022	SELL	$595.12 - $698.43 $86,887 - $101,970	-146 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$543.48 - $670.97 $79,348 - $97,961	146 New	146 $93,000

1,516

82.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $73.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.